Healthy men to test cancer Drug's new recipe

NCT ID NCT07619001

Not yet recruiting Knowledge-focused Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks whether AK104, an experimental cancer drug, behaves the same in the body when made at a new manufacturing site versus the original site. It involves 158 healthy Chinese men who will get a single low dose of the drug. The goal is to compare drug levels in the blood, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AK104 (anti-PD-1/CTLA-4 bispecific antibody)

What this could lead to

If successful, this could confirm that the drug made at the new site is equivalent to the original, supporting broader manufacturing flexibility.

What could go wrong

This is an early-phase study in healthy volunteers, not patients. It only checks drug levels in the blood, not whether the drug works for any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY MALE ADULTS PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhejiang Xiaoshan Hospital

    Hangzhou, Zhejiang, China